Transcriptional profiling of Chinese medicinal formula Si-Wu-Tang on breast cancer cells reveals phytoestrogenic activity by Mandy Liu et al.
Liu et al. BMC Complementary and Alternative Medicine 2013, 13:11
http://www.biomedcentral.com/1472-6882/13/11RESEARCH ARTICLE Open AccessTranscriptional profiling of Chinese medicinal
formula Si-Wu-Tang on breast cancer cells reveals
phytoestrogenic activity
Mandy Liu1, Jeffery Fan1, Steven Wang1, Zhijun Wang1, Charles Wang2, Zhong Zuo3, Moses SS Chow1,
Leming Shi4,5, Zhining Wen4,6* and Ying Huang1*Abstract
Background: Si-Wu-Tang (SWT), comprising the combination of four herbs, Paeoniae, Angelicae, Chuanxiong and
Rehmanniae, is one of the most popular traditional oriental medicines for women’s diseases. In our previous study,
the microarray gene expression profiles of SWT on breast cancer cell line MCF-7 were found similar to the effect of
β-estradiol (E2) on MCF-7 cells in the Connectivity Map database.
Methods: Further data analysis was conducted to find the main similarities and differences between the effects of SWT
and E2 on MCF-7 gene expression. The cell proliferation assay on MCF-7 (ER-positive) and MDA-MB-231 (ER-negative)
cells were used to examine such estrogenic activity. The estrogenic potency of SWT was further confirmed by
estrogen-responsive element (ERE) luciferase reporter assay in MCF-7 cells.
Results: Many estrogen regulated genes strongly up-regulated by E2 were similarly up-regulated by SWT, e.g., GREB1,
PGR and EGR3. Of interest with regard to safety of SWT, the oncogenes MYBL1 and RET were strongly induced by E2 but
not by SWT. Quantitative RT-PCR analysis revealed a highly concordant expression change in selected genes with data
obtained by microarrays. Further supporting SWT’s estrogenic activity, in MCF-7 but not in MDA-MB-231 cells, SWT
stimulated cell growth at lower concentrations (< 3.0 mg/ml), while at high concentrations, it inhibits the growth of
both cell lines. The growth inhibitory potency of SWT was significantly higher in MDA-MB-231 than in MCF-7 cells. The
SWT-induced cell growth of MCF-7 could be blocked by addition of the estrogen receptor antagonist tamoxifen. In
addition, SWT was able to activate the ERE activity at lower concentrations. The herbal components Angelicae,
Chuanxiong and Rehmanniae at lower concentrations (< 3.0 mg/ml) also showed growth-inducing and ERE-activating
activity in MCF-7 cells.
Conclusions: These results revealed a new mechanism to support the clinical use of SWT for estrogen related diseases
and possibly for cancer prevention. This study also demonstrated the feasibility of using microarray transcriptional
profiling to discover phytoestrogenic components that are present in natural products.
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Oriental medicinal herbs provide a promising source to
develop orally effective, non-toxic, complementary and
alternative medicine (CAM) modality for cancer pre-
vention. Si-Wu-Tang [SWT, Si-Wu decoction (Chinese
name), Samultang (Korean name), or Shimotsu-to
(Japanese name)], comprising the combination of four
herbs, Paeoniae, Angelicae, Chuanxiong and Rehmanniae,
is one of the most popular traditional oriental medi-
cines for women’s health [1]. It has been used in Eastern
Asia for about one thousand years for various
women’s diseases and ranks first as the most fre-
quently used Chinese medicines in several surveys [2].
It is an inexpensive over-the-counter preparation used
for the relief of menstrual discomfort, climacteric syn-
drome, peri- or postmenopausal syndromes and other
estrogen-related diseases [1-5]. The major principle of
SWT therapy as Chinese Medicine is to improve a de-
ficiency of Qi and Blood [6]. SWT has shown seda-
tive, anti-coagulant and anti-bacterial activities as well
as protective effect on radiation-induced bone marrow
damage in model animals [7,8]. Several in vitro and
in vivo studies show a preventive effect of SWT on
endometrial carcinogenesis induced by carcinogen and
estrogen [9,10], although the mechanisms and active
constituents are unknown. In a pilot clinical trial on
the effects of SWT in the treatment of primary dys-
menorrhoea, the administration of SWT was well toler-
ated without any adverse reactions [2]. Another clinical
study demonstrated that SWT can be integrated as an
alternative therapy within Western medicine [11].
Despite the wide use of SWT for women’s diseases, lit-
tle is known for its potential estrogenic properties. In our
previous study [12], the microarray gene expression pro-
files of SWT on human breast cancer cell line MCF-7
were compared with 1,309 compounds in the “Connect-
ivity Map” (cMAP) reference database [13]. The profile
of SWT-treated MCF-7 cells showed the highest match
with that of estradiol (E2)-treated MCF-7 cells in the
cMAP database [12], consistent with SWT’s widely
claimed use for women’s diseases and suggesting an
estrogen-like effect. Such results indicate that SWT may
contain phytoestrogen(s), which are a diverse group of
plant-derived compounds that structurally or function-
ally mimic endogenous estrogens [14]. Many lines of evi-
dence suggested that phytoestrogens not only may be
useful as an alternative and complementary approach for
hormone replacement therapy, but also for the preven-
tion of breast or prostate cancers [15,16]. Studies on phy-
toestrogens over the past few decades has greatly
increased, although these research results indicate both
health benefit and risk for the application of phytoestro-
gens [17]. A recent survey reported that almost 30% of
women sought CAM therapies such as soy or otherherbal products, to combat postmenopausal discomfort
[18]. As the number of women who seek the use of
herbal medicinal products is increasing, new methods
are required to evaluate the efficacy and adverse reac-
tions of phytoestrogen components.
It has been previously reported that phytoestrogens
and the natural estrogens such as E2 can induce a similar
effect on gene expression profiles of a panel of “estrogen-
responsive genes” [19]. DNA microarray – based expres-
sion profiling has been used as a genomic approach for
the characterization of compounds with estrogen-like ac-
tivities. For examples, a customized DNA microarray
containing 172 estrogen-responsive genes have been used
to evaluate the effect of multiple well known phytoestro-
gens including genistein and daidzein [19], and the in-
dustrial endocrine disruptors including zearalenone,
diethylstilbestrol and dioxin [20-23]. These results
obtained using DNA microarrays were consistent with
those derived from other bioassays that are used for
detecting estrogenic activity, such as ligand-binding and
reporter gene assays. However, this genomic approach
has not yet been applied to herbal products used in
oriental medicines. Moreover, including only selected
gene sets in customized DNA microarray may result in
a bias in gene selection. Therefore, we hypothesize that
the whole genome expression analysis based on avail-
able microarray datasets can provide a comprehensive
and unbiased approach to identifying new phytoestro-
gens from natural products or dietary components, re-
vealing novel mechanisms, and/or providing a quality
control for the evaluation of natural products with
phytoestrogen components.
The purpose of the present study is to examine the
phytoestrogenic effect of SWT using the whole human
genome microarray analysis followed by pharmacological
studies. We firstly re-analyzed the microarray gene ex-
pression data to find the similarities and differences be-
tween the effect of SWT and E2 on gene expression of
MCF-7 cells. Real-time RT-PCR analysis was used to val-
idate the microarray data. Cell growth and estrogen re-
ceptor assays were used to confirm the findings from
genomic analysis. This study provides insights in under-
standing the complex actions of SWT as a potential es-
trogen receptor modulator and scientific evidence to
support the empirical clinical use of SWT.
Methods
Compounds
17 β-estradiol, tamoxifen, 4-OH tamoxifen and DMSO
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Preparation of SWT extracts
The SWT products and its four single herb extracts
were obtained from the School of Pharmacy, Chinese
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factured under GMP condition at the Hong Kong Insti-
tute of Biotechnology (Hong Kong, China) according to
the protocol described in Chinese Pharmacopoeia 2005
[24] with modifications. The standard adult dosage of
SWT extracts is 15 grams per day [11]. Crude water
extracts were prepared from powdered SWT. Fresh
extracts were prepared right before the experiment. The
extract was prepared by dissolving the powder into PBS
buffer or culture medium, followed by sonication for
30 min.
Cell lines and cell culture
The MCF-7 cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA), cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 1%
non-essential amino acids, 100 unit/mL penicillin,
100 μg/mL streptomycin, 1 mM sodium pyruvate, and
2 mM L-glutamine in an atmosphere of 5% CO2 at
37°C. For microarray analysis, the cells were seeded in
6-well plates at a density of 1 × 105 cells/ml. After in-
cubating for 24 hours and at least 4 days before treat-
ment, the medium was then replaced by hormone free
medium which contains phenol-red free DMEM
medium supplemented with 5% charcoal-dextrin
stripped FBS (CD-FBS) to prevent the influence of
hormones or estrogen-like compounds in the regular
culture medium. The MCF-7 cells were then incubated
with hormone free medium and treated by 0.001%
DMSO (vehicle control group, C), 0.1 μM 17 β-estradiol
(EM), 0.0256, 0.256, and 2.56 mg/ml SWT (SL, SM
and SH) for 6 hours. The concentrations of SWT were
determined based on previous in vitro studies [25].
Three replicates for each of the five treatment groups
were analyzed. The detailed experimental information
including names and concentrations of the treatments
are shown in previous report [12].
RNA extraction and microarray processing
Total RNA was extracted using RNeasy Mini Kit (QIAGEN,
Valencia, California), following the manufacturer’s proto-
col. The concentrations of RNA were measured by a
NanoVue Plus (GE Healthcare, Piscataway, NJ, USA) and
adjusted to 0.2 μg/μl. The RNA samples were stored at
−80°C before further processing for microarray analysis
or cDNA synthesis. Method of microarray processing is
reported [12].
Microarray data analysis
Microarray data specifically generated for this study
are MIAME compliant. The raw data are available
through the National Center for Biotechnology Infor-
mation’s Gene Expression Omnibus (GEO series accessionnumber: GSE23610). The microarray gene expression
data were imported to ArrayTrack [26], a software sys-
tem developed by the U.S. Food and Drug Administra-
tion’s National Center for Toxicological Research for the
management, analysis, visualization and interpretation
of microarray data (http://www.fda.gov/ArrayTrack/).
The software of CLUSTER and
TREEVIEW were used to cluster and visualize the data
by using the correlation metric and average linkage [27].
For each probeset, log2-transformed intensity data were
used in a two-sample t-test to obtain a p value and a fold
change (FC).
Real-time RT-PCR
To validate the microarray results, one microgram of
total RNA was incubated with DNase I, and reverse
transcribed with oligo dT using Superscript II RT-PCR
(Invitrogen). One microliter of RT product was ampli-
fied by primer pairs specific for GREB1, PGR, MYBL1,
RET and ST8SIA4. The GAPDH gene was used as a nor-








CATT-30 and 50-CTTAGGGAAGGGCCAGAATC-30; GA
PDH: 50-AGCCACATCGCTCAGACAC-30 and 50-GCC
CAATACGACCAAATCC-30. Relative gene expression was
measured using the GeneAmp 7300 Sequence Detection
system (Applied Biosystems, Foster City, CA, USA) using a
SYBR Green protocol. For all amplifications, a standard
amplification program was used (1 cycle of 50°C for 2 min,
1 cycle of 95°C for 10 min, 50 cycles of 95°C for 15 s and
60°C for 1 min). At the end of PCR cycling steps, data for
each sample was displayed as a melting curve. The ABI
SDS software was used to determine a “Cycle Threshold”
(Ct), which was the cycle number where the linear phase
for each sample crossed the threshold level. All samples
were run in triplicate with no-template control.
Cell proliferation assay
Growth-inhibitory activity on MCF-7 and MDA-MB-231
cells was tested using a proliferation assay with sulforho-
damine B (SRB), a protein-binding reagent (Sigma), or
MTS assay (Promega) as described before [28]. Both
SRB and MTS assays showed consistent results and
therefore were used interchangeably. 2000–5000 cells/
well were seeded in 96-well plates and incubated for
24 h in RPMI-1640. The medium was then replaced by
hormone free medium which contains phenol-red free
DMEM medium supplemented with 5% CD-FBS 3 days
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with hormone free medium and treated by test agents
added in a dilution series in three or six replicate wells
for incubation of days designated in Results. To deter-
mine IC50 values, the absorbance of control cultures
without drug was set at 1. Dose–response curves were
plotted using GraphPad Prism (San Diego, California).
Each experiment was performed independently at least
twice. Student’s t test was used to determine the degree
of significance.
Luciferase reporter gene assay
The MCF-7 cells were cultured in hormone-free
medium for three days and then plated in 96-well plates.
The luciferase reporter construct ERE-luc was a gift
from Dr. David Sanchez at Western University of Health
Sciences. The MCF-7 cells were transfected with the
ERE-luc plasmid and a constitutively active renilla luci-
ferase (pRL-TK-luc, from Promega; to correct for trans-
fection efficiency) (10:1 ratio) using FuGENE HD
Transfection Reagent (Roche Applied Science, Indian-
apolis, IN) according to the manufacturer’s instructions.
24 hours after transfection, the cells were exposed to the
extracts of SWT or components, or E2 (10 nM), in the
presence or absence of tamoxifen, for another 24 hours.
Cell lysates were used for determining luciferase activ-
ities of both firefly and renilla by the dual luciferase re-
porter gene assay (Promega). Firefly luciferase activity
was normalized to renilla luciferase activity. Each experi-
ment was carried out in triplicate and expressed as the
mean ± Standard Error (SE). Student’s t test was used to
determine the degree of significance.
Results
Comparison of the expression changes induced by SWT
and E2
Spearman correlation analysis was applied to assess the
overall similarity of the gene expression profiles between
E2 and SWT in three concentrations (SH, SM and SL)
using all the 54,675 probes on the microarrays. The cor-
relations with E2 were significant for all the SWT con-
centrations in the order of SM (r = 0.62, P < 0.0001) > SL
(r = 0.57, P < 0.0001) > SH (r = 0.43, P < 0.0001) (Figure 1A).
The correlation was confirmed by hierarchical clustering
analysis (Figure 1B). This genome-wide analysis indicates
that gene expression of low- and medium-concentration
SWT treatments (SM and SL) showed certain similarity
with E2 treatment, while the high concentration SWT
(SH) induced a gene expression changes more distinct with
E2 treatment, possibly due to a dramatic treatment effect
of high concentration of SWT.
The treatment by E2 resulted in large numbers of
genes differentially expressed in MCF-7 cells in compari-
son with the vehicle controls. Applying the initial cutoff,t-test P value < 0.05 and fold change > 1.5, the treat-
ment with E2 changed the expression of 830 unique
genes (corresponding to 1,292 probe sets). We applied
a more stringent selective filter to reduce the 1,292
E2-responsive probe sets to a 45-probe subset for further
analysis (Table 1). The list includes genes that showed
strongest up-regulation or down-regulations induced by E2
by applying a filtering cutoff, fold change > 4 for up-
regulated genes, fold change < 0.4 for down-regulated
genes, and false discovery rate (FDR) < 0.01. Since the same
microarrays (Affymetrix Human Genome U133 Plus 2.0)
have been used in several previous studies for the analysis
of MCF-7 cells treated with E2 for 3, 6 or 12 hours [29-31],
we compared the data derived from these studies available
at the NCBI GEO Profiles at the site http://www.ncbi.nlm.
nih.gov/geoprofiles. All of the 45 probes show the same
trend of E2-induced up- or down-regulation for at least 2
folds in comparison with the controls. Therefore, although
it is impossible for the selected 45 probes to include the
whole set of genes regulated by the estrogen receptors, we
believe that such selection represents a subset of reliable
“estrogen-responsive genes” or “fingerprint of estrogen
treatment” on the MCF-7 cells. Shown in Table 1, many
genes strongly up-regulated by E2 were similarly up-
regulated by SWT although to a lower degree, e.g.,
C14orf182, PGR, RBM24, GREB1, RERG, SGK3, all of
which are well-known estrogen regulated genes. Of interest
with regard to cancer prevention, the oncogenes MYBL1,
RET and cyclin D1 (not listed in Table 1) is strongly
induced by E2 but marginally by SWT (Table 1).
Spearman correlation analysis was also applied to as-
sess the similarity of the gene expression profiles between
E2, SH, SM and SL using the selected 45 probes on the
microarrays, named as “estrogen-responsive genes”. By
focusing on the small subset of genes highly related to E2
regulation, the correlation between E2 and SWT treat-
ments was greatly increased. In particular, the correlation
between E2 and SH increased to be the highest among all
the concentrations of SWT tested. The correlations were
significant for all the SWT concentrations in the order of
SH (r = 0.79, P < 0.0001) > SM (r = 0.69, P < 0.0001) > SL
(r = 0.56, P < 0.0001) (Figure 2A). The correlation was
similarly confirmed by hierarchical clustering analysis
(Figure 2B). A high correlation coefficient (colored in red
in the heatmap of Figure 2B) means that the gene expres-
sion profiles from two microarrays are very similar. This
result indicates that by filtering out gene expression
changes induced by high concentration SWT which is
not related to the phytoestrogenic activity, the SWT
treatments at all concentrations showed a high degree of
similarity as the E2 treatment.
We next performed hierarchical cluster analyses to
group the 15 cell samples (the vehicle control group C,
the E2 group EM, and the SWT groups in three
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Figure 1 Similarity between SWT and E2 treatment examined using whole genome DNA microarray. (A) Scatterplot graph shown as the
comparison of gene expression profiles between E2 and SWT treatment at various concentrations (SH, SM and SL). The axes show log2 FC
calculated for each of the treatment condition (FC: fold change, derived from intensity for treatment/intensity for control). The Spearman
correlation coefficient (R) between two profiles was calculated for each graph. P < 0.0001 for all the correlations. (B) The hierarchical clustering
analysis and heatmap of the correlation coefficients of the gene expression profiles based on log2 FC for each treatment group. This genome-
wide analysis shows that the low- and medium-concentration SWT treatments (SM and SL) showed higher similarity with E2 treatment, while the
high concentration SWT (SH) induced a gene expression changes less similar with E2 treatment.
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estrogen-responsive genes on the basis of the gene ex-
pression pattern. Figure 3 shows that the profiles of
MCF-7 cells treated with E2 and SH were similar but
distinguishable, while both of the E2 and SH treatment
groups showed dramatically different profiles compared
to that of the control, SL and SM groups. The 45 genes
can be clearly clustered into two gene groups, 36 E2-up-
regulated probes and 9 E2-down-regulated probes. The
different probes for the same genes, such as C14orf182,
TMEM164, SGK3 and ST8SIA4, were clustered together,
further indicating the consistency in their gene expres-
sion pattern. Most E2-up-regulated genes (colored in red
in the heatmap indicating increased expression) showed
lower degree of up-regulation in SH treatment, except
for the EGR3 gene showing the same extent of up-
regulation for both E2 and SH treatments. For a subset
of genes, including SGK3, RERG, MYBL1, CYP26B1,
RET, HCK and CDCA7, SH treatment only marginally
induced the gene expression. Interestingly, E2 and SH
showed the opposite effect on CYP1A1 expression: The
CYP1A1 gene was downregulated by E2 but up-
regulated by SH. This difference can also be seen on the
scatterplot shown in Figure 2A.Most SWT-responsive genes not affected by E2
The gene expression changes induced by treatment of
SWT showed a dose-responsive trend, resulting changes
in 1,911 unique genes (corresponding to 2,979 probe
sets) from treatment with the highest concentration
(SH). We applied the same criteria to identify the SWT
responsive probe sets. A total of 131 probes were
selected based on the filtering cutoff of fold change > 4
for up-regulated genes, fold change < 0.4 for down-
regulated genes. These include 70 probes that showed
strongest up-regulation and 61 probes with strongest
down-regulations induced by SH treatment. We per-
formed hierarchical clustering analyses to group the cell
samples and the 131 SWT responsive genes on the basis
of the gene expression pattern. Figure 4 shows that the
profiles of cell samples treated with E2 and SH are obvi-
ously different. Unlike the E2 responsive genes shown in
Table 1 and Figure 3, only small subset of SWT respon-
sive genes were similarly induced by E2, including only a
small group of genes in cluster A and B, which include
E2-responsive genes identified in Table 1. The majority
of SWT up-regulated genes were not up-reguated by E2.
This may result from the high concentration used for
SH treatment (2.56 mg/ml), as high concentration may
Table 1 Expression changes of estrogen-responsive genes in MCF-7 cells treated with E2 and SWT
Fold change (treatment/control)
Affymetrix probe ID Gene symbol Description E2 SH SM
Up-regulated genes
237460_x_at C14orf182 chromosome 14 open reading frame 182 13.77 6.29 1.18
228554_at PGR progesterone receptor 12.10 2.83 1.72
205862_at GREB1 growth regulation by estrogen in breast cancer 1 10.87 5.08 2.37
206115_at EGR3 early growth response 3 10.69 10.70 1.65
235004_at RBM24 RNA binding motif protein 24 10.23 6.07 1.57
1557277_a_at 8.71 2.08 1.32
231120_x_at PKIB protein kinase (cAMP-dependent, catalytic) inhibitor beta 7.96 2.29 1.27
219525_at SLC47A1 solute carrier family 47, member 1 7.93 2.22 1.40
205440_s_at NPY1R neuropeptide Y receptor Y1 7.08 2.81 1.84
44790_s_at C13orf18 chromosome 13 open reading frame 18 7.08 2.97 2.59
213906_at MYBL1 v-myb myeloblastosis viral oncogene homolog (avian)-like 1 6.78 1.26 1.29
220038_at SGK3 serum/glucocorticoid regulated kinase family, member 3 6.63 1.79 1.51
222921_s_at HEY2 hairy/enhancer-of-split related with YRPW motif 2 6.11 2.88 1.59
228241_at AGR3 anterior gradient homolog 3 (Xenopus laevis) 6.08 2.55 1.84
204798_at MYB v-myb myeloblastosis viral oncogene homolog (avian) 5.96 2.37 1.92
227627_at SGK3 serum/glucocorticoid regulated kinase family, member 3 5.83 1.69 1.54
208018_s_at HCK hemopoietic cell kinase 5.77 1.33 1.02
239777_at C14orf182 chromosome 14 open reading frame 182 5.63 3.29 1.27
207886_s_at CALCR calcitonin receptor 5.38 2.59 1.86
232306_at CDH26 cadherin 26 5.37 3.51 1.94
219743_at HEY2 hairy/enhancer-of-split related with YRPW motif 2 5.30 1.83 1.37
208305_at PGR progesterone receptor 5.22 1.69 1.10
223551_at PKIB protein kinase (cAMP-dependent, catalytic) inhibitor beta 5.18 2.13 1.42
211421_s_at RET ret proto-oncogene 4.98 1.54 1.19
205326_at RAMP3 receptor (G protein-coupled) activity modifying protein 3 4.67 2.35 1.87
244745_at RERG RAS-like, estrogen-regulated, growth inhibitor 4.61 1.43 1.51
237334_at 4.55 2.25 1.34
219702_at PLAC1 placenta-specific 1 4.45 2.02 1.09
223201_s_at TMEM164 transmembrane protein 164 4.44 1.68 1.23
219825_at CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 4.42 1.26 1.19
224428_s_at CDCA7 cell division cycle associated 7 4.39 1.11 1.45
209687_at CXCL12 chemokine (C-X-C motif) ligand 12 4.31 1.77 1.29
242064_at SDK2 sidekick homolog 2 (chicken) 4.25 1.48 0.99
219985_at HS3ST3A1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 4.17 2.01 1.40
220486_x_at TMEM164 transmembrane protein 164 4.09 1.64 1.22
201739_at SGK1 serum/glucocorticoid regulated kinase 1 4.01 1.86 1.29
Down-regulated genes
242943_at ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 0.31 0.40 0.85
202948_at IL1R1 interleukin 1 receptor, type I 0.32 0.40 0.78
229354_at AHRR aryl-hydrocarbon receptor repressor 0.33 0.83 0.80
230261_at ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 0.36 0.41 0.88
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Table 1 Expression changes of estrogen-responsive genes in MCF-7 cells treated with E2 and SWT (Continued)
230836_at ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 0.37 0.35 0.88
228176_at EDG3 endothelial differentiation, sphingolipid G-protein-coupled receptor, 3 0.38 0.67 0.95
205749_at CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 0.38 1.76 0.97
213413_at BG434174 STON1 0.39 0.27 0.63
Gene expression of MCF-7 cells after 6 hours of treatment with 0.1 μM E2 or SWT (2.56, 0.256 or 0.0256 mg/ml) was analyzed by microarrays. Listed are selected
genes that showed strongest up-regulation or down-regulations induced by E2 by applying the cutoff of fold change > 4 for up-regulated genes, fold change < 0.4
for down-regulated genes, and false discovery rate (FDR) < 0.01. Expression values are shown by fold changes between treatment and control, i.e., expression
values relative to untreated control cells for E2, SH and SM. Fold changes in bold: FDR < 0.01.
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represent the pharmacological action. Therefore, genes
showing dose-dependent changes after SWT treatment are
particularly interesting to us. The genes in cluster C are
those dose-dependently regulated by SWT, including many
genes in the nuclear factor erythroid 2-related factor 2
(Nrf2) cell protective pathways, such as HMOX1, GCLM
and SLC7A11. However, E2 treatment didn’t affect expres-
sion of these genes. This represents one of the major differ-
ences between E2 and SWT treatment.
Microarray gene expression validated by real-time RT-PCR
The differential expression of five E2 responsive genes in
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Figure 3 Cluster analysis of expression profiles of 45 estrogen-responsive probes after treatment with E2 or SWT. Gene expression
profiles were obtained after treatment with 100 nM of E2 (EM), 0.0256, 0.256 and 2.56 mg/ml SWT (SL, SM and SH). The results of microarray
analysis are shown as values of log2 fluorescent intensity. The branch lengths of the clustering tree reflect the degree of similarity of gene
expression. Columns represent the gene expression levels in individual samples; rows represent individual genes. Red and green indicate
transcript levels above and below the median for each gene across all samples, respectively.
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http://www.biomedcentral.com/1472-6882/13/11Dose-dependent effects of SWT and its components on
growth of breast cancer cells
To examine the effects of SWT on the growth of
breast cancer cells, MCF-7 cells were treated with
various concentrations of SWT for 2–6 days. At low
(1.5 and 3 mg/ml) concentrations, SWT stimulated
MCF-7 cell growth (Figure 6); in contrast, SWTinhibited cell growth at a higher (6 and 12 mg/ml)
concentration, revealing a dose-dependent activity of
SWT on cell growth.
We next compared the effects of E2 and SWT pro-
liferation of MCF-7 (ER+) and MDA-MB-231 (ER-)
cells (48 hour treatment). Data in Figure 7A show
that E2 stimulated MCF-7 cell proliferation. This effect




Figure 4 Cluster analysis of expression profiles of 131 SWT-responsive probes after treatment with E2 or SWT. Gene expression profiles
were obtained after treatment with 100 nM of E2 (EM), 0.0256, 0.256 and 2.56 mg/ml SWT (SL, SM and SH). The results of microarray analysis are
shown as values of log2 fluorescent intensity. The branch lengths of the clustering tree reflect the degree of similarity of gene expression.
Columns represent the gene expression levels in individual samples; rows represent individual genes. Red and green indicate transcript levels
above and below the median for each gene across all samples, respectively. Gene clusters denoted by the bars and letters A and B are groups
containing estrogen-induced genes. Gene cluster C is the group containing genes induced by SWT in dose dependent manner but not induced
by E2. The gene groups A and C are zoomed and the expression patterns with gene names are shown on the right.
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http://www.biomedcentral.com/1472-6882/13/11was statistically significant at all the concentrations
tested (0.1, 1, 10 and 100 nM) (P < 0.01). SWT showed
stimulatory effect on MCF-7 cell proliferation at lower
concentration (1.5 and 3 mg/ml) (P < 0.05), while at
higher concentration (12 mg/ml) it exhibited a statisti-
cally significant cytotoxic effect (P < 0.01) (Figure 7A).
On the contrary, neither E2 nor SWT displayed any de-
tectable stimulatory effect on MDA-MB-231 cell prolif-
eration (P > 0.05), while SWT significantly inhibited
MDA-MB-231 cell proliferation in a dose dependent
fashion (P < 0.01 for all the concentration tested)
(Figure 7B). The cytotoxic effect of SWT on MDA-MB-
231 (IC50 = 4.5 ± 0.21 mg/ml) was significantly stronger
than that on MCF-7 cells (IC50 >12 mg/ml) (P < 0.01).We also assessed the combined effect of SWT and
tamoxifen (TAM) on MCF-7 and MDA-MB-231 cell
growth. Treatment with TAM (5 μM) alone did not
affect the growth of both cell lines (Figure 8A and 8B).
The growth stimulatory activity of SWT in MCF-7
cells at all concentrations was abolished by TAM
treatment, indicating the ER-dependency of such ac-
tivity of SWT. Co-treatment of MCF-7 cells with
SWT and 5 μM TAM resulted in significantly
increased inhibition of cell proliferation (P < 0.05)
(Figure 8A). However, co-treatment of MDA-MB-231
cells with SWT combined with TAM did not result in
statistically significant difference compared with SWT















































































































































Figure 5 Validation of microarray results by real-time RT-PCR. Microarray data (a-e) for five genes (GREB1, PGR, MYBL1, RET and ST8SIA4) were
compared with the results obtained by quantitative real-time RT-PCR (f-j). Each experiment was repeated three times and the average and S.D.
are shown. *, P < 0.05.
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http://www.biomedcentral.com/1472-6882/13/11We next examined the effects of four components of
SWT, Paeoniae, Angelicae, Chuanxiong and Rehmanniae,
on MCF-7 and MDA-MB-231 cell proliferation.
Results in Figure 9A shows Angelicae, Chuanxiong
and Rehmanniae, but not Paeoniae, increased thegrowth of MCF-7 cells at low concentration (1.5 or
3 mg/ml), although such effect was not statistical sig-
nificant (P > 0.05). At higher concentration, all of the
components showed cytotoxicity. In MCF-7 cells, the




































Figure 6 Dose-dependent effects of SWT on MCF-7 cell
proliferation. To determine time- and dose-dependent growth
rates of MCF-7 cells in the presence of SWT, cells were plated in 96-
well plates (2,000 per well) in hormone-free medium for indicated
times and cell growth was determined by MTS assay. Results are
expressed as relative growth rate to the control cells with no drug
treatment. Points, means from six replicates; bars, S.D. * p < 0.05 for
all treatment groups compared to untreated control.
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http://www.biomedcentral.com/1472-6882/13/110.16) > Angelicae (IC50 = 3.1 ± 0.073) > Chuanxiong (IC50 =
5.7 ± 0.57) > Rehmanniae (IC50 >12). In MDA-MB-231
cells, the cytotoxicity is in the same order of Paeo-
niae (IC50 = 1.1 ± 0.21) > Angelicae (IC50 = 2.8 ± 0.20) >






























































Figure 7 Effects of E2 or SWT on cell growth of MCF-7 (A) and MDA-M
per well) were treated with E2 or SWT for 48 hours, cell growth was measu
cells with no drug treatment. Points, means from three replicates; bars, S.DDose-dependent effects of SWT and its components on
estrogen receptor (ER) transcription activity
To confirm the estrogenic activity of SWT, we studied
the effect of SWT on ER-mediated gene transcription
using estrogen-responsive luciferase reporter assay.
The MCF-7 cells that had been transiently co-
transfected with the ERE-luciferase and a constitu-
tively active renilla luciferase plasmid (pRL-TK-luc)
were used to measure the formation of the functional
ER-ERE complex in response to treatment with the
E2 or SWT. Data were normalized to the renilla
plasmid transfection and then expressed as a fold in-
duction compared with untreated cells (Figure 10A).
E2 (10 nM) significantly increased luciferase activity
by 15 ± 1.7 fold (P < 0.01). SWT at concentration of
1.5 and 3.0 mg/ml had significant increased luciferase
activity by 1.6 ± 0.22 and 2.0 ± 0.31 fold inductions
(P < 0.05), respectively. All the four herbal compo-
nents of SWT showed ERE activation at 1.5 and
3.0 mg/ml. The statistical significance for the ERE in-
duction has been detected for Rehmanniae, Angelicae
and Chuangxiong in dose-dependent manner (P < 0.05
for 1.5 mg/ml, P < 0.01 for 3.0 mg/ml), but not for
Paeoniae (P > 0.05), indicating Paeoniae may not be the
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Figure 8 Effects of SWT combined with tamoxifen on cell growth of MCF-7 (A) and MDA-MB-231 (B). The hormone-deprived cells
in 96-well plates (5,000 cells per well) were treated with SWT and/or tamoxifen (TAM) for 48 hours, cell growth was measured with SRB assay.
Results are expressed as percentage of control cells with no drug treatment. Points, means from three replicates; bars, S.D. *, P < 0.05; **, P < 0.01.
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http://www.biomedcentral.com/1472-6882/13/11We next investigated the impact of the estrogen antag-
onist tamoxifen on the estrogenic activity of SWT. Dual
luciferase assay on MCF-7 cells was performed to deter-
mine if 1 μM TAM would inhibit the effects of SWT
(1.5 and 3.0 mg/ml) in the ERE-regulated reporter. SWT
at both concentrations increased ERE-transcriptional ac-
tivation (Figure 10B) and such activation can be inhib-
ited by the co-treatment of the cells with TAM (P < 0.05
for SWT 3.0 mg/ml + TAM versus SWT alone), indicat-
ing the activities may be mediated via the activation of
the ER.
Discussion
The use of traditional herbal medicine is widespread in
China and other Asian countries, and is also rapidly
growing in Western countries [32]. Despite its long his-
tory of use, many questions remain to be answered, due
to lack of mechanistic understanding. In this study, we
demonstrated, using a whole human genome microarrayapproach, the phytoestrogenic mechanism for a popular
formula Si-Wu-Tang (SWT). Three major points are
highlighted: (1) this is the first study to use DNA
microarray-based gene expression analysis to reveal phy-
toestrogenic activity of herbal medicine. The similar ap-
proach can be used for other natural products; (2) The
genomic data were validated by the “gold standard”
method of gene expression study – quantitative RT-PCR;
and (3) the discovery was confirmed by pharmacological
assays such as cell proliferation and estrogen receptor
luciferase reporter assays on breast cancer cell lines. The
results presented here are very important for many
women taking SWT for various conditions and clinical
practitioners who recommend the use of SWT or other
CAM with similar phytoestrogenic activities.
SWT has been used in China for more than 1,000 years
for the relief of menstrual discomfort, climacteric syn-
drome, peri- or postmenopausal syndrome and other























































Figure 9 Effects of SWT components on cell growth of MCF-7 (A) and MDA-MB-231 (B). The hormone-deprived cells in 96-well plates
(5,000 cells per well) were treated with Paeoniae, Chuangxiong, Angelicae or Rehmanniae for 48 hours, cell growth was measured with SRB assay.
Results are expressed as percentage of control cells with no drug treatment. Points, means from three replicates; bars, S.D. *, P < 0.05; **, P < 0.01.
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http://www.biomedcentral.com/1472-6882/13/11composed of four herbs, Radix Rehmanniae praeparata
(Rehmanniae), Radix Angelicae Sinensis (Angelicae), Rhi-
zoma Ligustici Chuanxiong (Chuanxiong) and Radix
Paeoniae Alba (Paeoniae) [2]. At least nine bioactive
phytochemicals have been reported for SWT: paeoni-
florin, paeonol, gallic acid, ferulic acid, Z-ligustilide,
ligustrazine, butylphthalide, senkyunolide A and catalpol
[1]. In view of wide empiric use of SWT and known
chemical components already reported, we profiled the
gene expression of MCF-7 cells treated with SWT ex-
tract at the non-toxic concentration (2.56, 0.256 and
0.0256 mg/ml), its component ferulic acid (0.1, 1.0 and
10 μM) as well as β-estradiol (E2, 0.1 μM) using Affymetrix
microarray HG-U133Plus2.0, enabling almost complete
analysis of the transcriptome [12]. Notably, the expression
of genes in the nuclear factor erythroid 2-related factor 2
(Nrf2) cytoprotective pathway were the most significantly
affected by SWT, but not by β-estradiol (E2) or ferulic
acid [12]. Even though the Nrf2 pathway was identifiedas one of the main molecular targets of SWT, it is well
known that therapeutic effect of many herbal medicines
can be attributed from targeting multiple rather than sin-
gle molecular targets. The present study discovered that
the estrogen receptor (ER) pathway represents another
potential target of SWT.
Our hypothesis was derived from the “Connectivity
map” (cMAP) analysis, which is based on the compari-
son between the database containing microarray expres-
sion data (Affymetrix HG-U133A array) from cultured
cell lines (e.g., MCF-7) treated with 1,309 bioactive com-
pounds with known mechanism of action [13] and our
SWT expression data [12]. This analysis results a stron-
gest match between the profiles of MCF-7 cells treated
with SWT and those of the same cell line treated with
E2 in the cMAP database [12]. Such correlation suggests
an estrogenic effect of SWT. The array data for MCF-7
cells treated by E2 or SWT were further compared by





























































Figure 10 Effect of SWT and its components on the ERE luciferase activity in MCF-7 cells. The hormone-deprived MCF-7 cells were
transiently co-transfected with the ERE-luc construct and a plasmid encoding renillar luciferase (pGL4.74) using FuGENEW HD transfection reagent.
(A) The transfected cells were incubated in DMEM supplemented with 10% CD-FBS with E2 (10 nM), SWT or Paeoniae, Chuangxiong, Angelicae or
Rehmanniae (1.5 and 3 mg/ml) for 24 h prior to measurement of firefly and renillar luciferase activities using the dual luciferase reporter gene
assay. *, P < 0.05; **, P < 0.01, treatment versus control. (B) The transfected cells were treated with SWT 3 mg/ml or 1.5 mg/ml alone or + 1 μM
tamoxifen. *, P < 0.05 tamoxifen + SWT versus SWT alone. Data represent the mean + SE of experiments performed in triplicate.
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http://www.biomedcentral.com/1472-6882/13/11for the similarity and difference in the treatment effects.
Comparing the expression patterns using all the 54,675
probes representing all the genes in the human genome
or using 45 probes selected based on fold of expression
changes induced by E2, action of SWT is similar to E2
in particular when focusing on the 45-probe “estrogen-
responsive genes”. The 45 probes were selected using
very stringent criteria: fold change > 4 for up-regulated
genes, fold change < 0.4 for down-regulated genes, and
false discovery rate (FDR) < 0.01. Many of these genes
have been reported to be estrogen-responsive genes
in vitro or in vivo. In addition, all of the 45 probes were
consistently changed in expression in E2 treated MCF-7
cells according to public available data deposited at the
NCBI GEO Databases from three published studies
[29-31], which used the same array type as used in our
study (Affymetrix HG-U133Plus 2.0) and the cell line
(MCF-7). This result indicates that the 45 probes canreliably represent the E2 regulated genes and therefore
can be named as “estrogen-responsive genes” or “finger-
print of estrogen”. The correlation and clustering results
revealed that the gene expression profile of MCF-7 cells
for the “estrogen-responsive genes” was similarly chan-
ged by the treatment with E2 and SWT.
The list of genes includes well-known estrogen-regu-
lated genes, such as GREB1, EGR3, RERG, PGR, and
SGK3. Many of them can be induced by SWT. The gene
for progesterone receptor, PGR, is an estrogen-
responsive gene, whose expression has been shown to
indicate a responsive estrogen receptor pathway [33].
The expression of PGR in MCF-7 cells or in rats can be
induced by treatment with the phytoestrogens daidzein
[33] and resveratrol [34], respectively. Another estrogen
receptor target gene, GREB1 (growth regulation by es-
trogen in breast cancer 1), is involved in the estrogen
induced proliferation of breast cancer cells and has the
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endocrine therapy [35]. GREB1 can be up-regulated by
several herbal medicines with phytoestronic activity,
such as Chinese licorice (Glycyrrhiza uralensis) root
[36] and the stem bark of Fabaceae (Erythrina lysiste-
mon) [37] in MCF-7 cells. Our results demonstrated
that SWT up-regulated the GREB1 in dose-dependent
manner. Among the 45 selected “estrogen-responsive
genes”, highest up-regulation by SWT was found for
EGR3 (Early growth responsive gene 3). EGR3 is a
zinc-finger transcription factor and the bona fide target
gene for ER-α [38]. Estrogen-treated MCF-7 cells
showed rapid and robust induction of EGR3 [38]. The
selected 45 probes also include a few genes which have
not been reported as estrogen-responsive genes before,
such as RBM24 (RNA binding motif protein 24) and
SLC47A1 (solute carrier family 47, member 1). Three
probes for the ST8SIA4 (ST8 alpha-N-acetyl-neurami-
nide alpha-2,8-sialyltransferase 4) consistently showed
down-regulation by both E2 and SWT. The protein
product of ST8SIA4 is known to be involved in the
polysialylation of neural cell adhesion molecule
(NCAM), which has been linked to cancer develop-
ment and dissemination [39]. ST8SIA4 has not been
reported regulated by estrogen receptors. The real-time
PCR data showed a similar gene expression change of
select genes in the “estrogen-responsive genes”.
Nevertheless, not all the probes of “estrogen-
responsive genes” are regulated by SWT in the same
way as E2. The examples include oncogenes MYBL1,
RET and cyclin D1 (not listed in Table 1 due to lower
fold change), which is strongly induced by E2 but not by
SWT. Although the contribution of MYBL1, encoding
for the homolog of the oncogene MYB, to the develop-
ment of breast cancer is unknown, in a previous report
it was strongly induced by E2 but only marginally by
phytoestrogens such as curcumin [40]. Further study is
needed to investigate the role of MYBL1 and RET in es-
trogen induced breast cancer development. As MCF-7
(ER-positive) is a commonly used model for determining
estrogenic effects, the action through ER pathways could
be one of the mechanisms for SWT’s beneficial effect on
alleviating postmenopausal complaints.
The gene expression profiles for SWT and E2 also
showed a strong difference. A wider range of cellular
pathways and targets were affected by SWT but not E2.
Hence, the action of SWT on MCF-7 cells is multifa-
ceted. One of the most notable differences is the ability
to induce the Nrf2. Although Nrf2-mediated oxidative
stress response was identified as the pathway most sig-
nificantly changed among differentially expressed genes
showing dose-dependent response to SWT treatment,
this trend has not been observed for E2 treatment. This
finding suggests that SWT could have cancer preventiveeffect. The role of estrogen in the initiation and progres-
sion of breast cancer has been well known [41]. However,
there is a large body of evidence that the consumption of
phytoestrogens derived from natural products can de-
crease the risk of cancer although they display estrogen-
like activity [42]. These results support a notion that
SWT may not have the cancer-causing effects of estra-
diol, but have the beneficial cell protective activity.
To confirm the phytoestrogenic action of SWT, we
examined the effect of SWT alone or in combination
with tamoxifen, on the growth of estrogen-dependent
MCF-7 cells and estrogen-independent MDA-MB-231
breast cancer cell lines. Firstly we found that SWT, simi-
lar to E2, can stimulate the proliferation of MCF-7 cells,
but not MDA-MB-231 cells. Such effect is dose-
dependent. At low concentrations, SWT stimulated cell
growth, while at high concentrations, SWT showed cyto-
toxicity. On the MDA-MB-231 cells, SWT failed to show
any growth stimulating effect, but has stronger cytotoxic
effect than MCF-7 cells. Thus, the growth stimulating
effect may be mediated by the ER, while the cytotoxic ef-
fect of SWT on both MCF-7 and MDA-MB-231 cells
may involve estrogen receptor-independent pathways.
These results are in agreement with those of Chang
et al. (2006) who reported SWT and its constituent feru-
lic acid caused MCF-7 cell proliferation [25,43]. While
in general SWT have relative safe record in clinical
usage, potential harmful effects may exist for patients
with breast cancer. In particular for ER-positive breast
cancer, use of SWT may promote the tumor cell growth
and counteract the effects of estrogen-deprivation treat-
ment by tamoxifen or aromatase inhibitors. Similar
issues have been raised for other phytoestrogens [14].
The growth inducing effect can be attenuated by the
treatment with tamoxifen, an antagonist of the estrogen
receptor, further indicating such effect may be ER-
dependent. Tamoxifen inhibits E2-mediated effects by
competing for receptor binding [44]. Although tamoxi-
fen alone did not affect the growth of MCF-7 and MDA-
MB-231 cells, co-treatment of SWT and tamoxifen
resulted in a dose-dependent decrease in cell growth.
Such combined effect was significant for SWT concen-
tration as low as 1.5 mg/ml. This effect was not signifi-
cant in the MDA-MB-231 cells. Thus, this combined
growth inhibitory effect may be mediated by estrogen re-
ceptor dependent mechanism. Over the last decade,
breast cancer prevention has focused mainly on endo-
crine therapies using selective estrogen receptor modula-
tors such as tamoxifen. The use of tamoxifen is able to
reduce incidence of ER-positive cancer in high-risk
women [44]. However, tamoxifen have not been widely
adopted as a preventive strategy for long-term use, due
to lack of complete prevention as well as intolerable side
effects, including endometrial cancer, thromboembolic
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no effect in reducing the risk of ER-negative tumors. As
breast cancer remains a global public health challenge,
there is a need for developing effective and non-toxic
preventive agents. The chemoprevention effectiveness of
SWT alone or in combination with tamoxifen needs fur-
ther evaluation.
Because phytoestrogens structurally resemble estrogen,
these compounds may exert their effects primarily
through binding to ER, although usually with a weaker
affinity than endogenous estrogens [46]. There are two
types of ER, alpha (ER-α) and beta (ER-β), both mediat-
ing the action of physiological endogenous estrogens
(for reviews, see [46] and [47]). ER-α and ER-β differ in
their functions and tissue distributions. Studies in MCF-
7 breast cancer cells showed that ER-α exerts a prolifera-
tive effect while ER-β is not necessary for proliferation
but against the effects of ER-α [48]. Many phytoestro-
gens, including resveratrol, genistein, and daidzein, have
been shown able to bind both ER-α and ER-β and to
modulate the transcription of estrogen-responsive target
genes in a dose-dependent manner [48]. The four herbal
components of SWT were studied for their possible
estrogen-like activities using cell growth assay and ERE
luciferase assay. Our results indicate that Rehmanniae,
Angelicae and Chuangxiong are more likely contribute
to the overall phytoestrogenic activity of SWT. Paeoniae
is less likely to play a main role for the estrogenic effect
because it did not show significant effect on growth in-
duction and ERE activation in MCF-7 cells. However,
the cytotoxicity activity of Paeoniae on both MCF-7 and
MDA-MB-231 cells is the most potent among all the
herbal components. This result suggests that Paeoniae
may have a potential anticancer activity on both ER +
and ER- breast cancers. In a recently published work
[49], 38 compounds from SWT series were studied for
the binding to the ER-α using a stably-transfected
human breast cancer cell line MVLN. Among all the
compounds tested, 22 compounds, including organic
acids and flavones, showed estrogen-like activity at the
concentration higher than 20 μg/ml. These results indi-
cate that the overall estrogen-like activity of SWT is
attributed to multiple components and compounds. The
synergistic or antagonistic interactions of these compo-
nents remain to be studied. Further studies also need to
obtain the information for SWT components on the spe-
cificity and selectivity of targeting the ERs. Because acti-
vating ER-β may prevent breast cancer [50], such results
will be essential for the evaluation of SWT as a cancer
preventive agent.
Conclusions
Although SWT is a widely used oriental medicinal for-
mula, the scientific evidence to prove its efficacy or sideeffects remains insufficient. In this study, gene expres-
sion profiles obtained by genomic approach based on
DNA microarray analysis shed light on the new mo-
lecular mechanism of SWT. The identified novel phy-
toestrogenic activity of SWT supports its current use
for alleviating postmenopausal conditions and possibly
for breast or prostate cancer prevention. Since carcino-
genesis involves multiple abnormal genes/pathways,
using herbal medicines in cancer prevention may be
superior to the agents targeting a single molecular tar-
get. The application of SWT, due to of its low cost
and low toxicity, may have a profound impact on
human health. Further work is needed to determine
the in vivo relevance of the in vitro findings obtained
from the present study. The approach used in this
study, genomic analysis following by functional valid-
ation, proved to be powerful in an understanding of
mechanisms of actions for CAM as exemplified by our
study with SWT. There is a potential to apply this ap-
proach for many other CAM and natural products. Fur-
thermore, the gene expression changes identified in this
study could be used as biomarkers for assessing the in-
tact quality of SWT or its series decoctions including
Xiang-Fu-Si-Wu decoction, Tao-Hong-Si-Wu decoction,
Qin-Lian-Si-Wu decoction, and Shao-Fu-Zhu-Yu decoc-
tion. The genomic approach can be integrated with trad-
itional chromatography-based fingerprinting method,
metabolomics, and pharmacological assays to obtain a
complete understanding of herbal medicines.
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